Nat Commun:前馈α粒子放射治疗能够根治雄激素受体依赖的前列腺癌

2018-04-30 AlexYang MedSci原创

人类激肽释放酶肽酶2(hk2)是一种前列腺特异性酶,它的表达受雄激素受体(AR)控制。AR是前列腺癌(PCa)的核心致瘤驱使因子,并且在癌症的DNA修复过程是是关键的调控因子。最近,有研究人员报道了一个创新的治疗策略,该策略利用了激素-DNA修复回路来促使分子特异性的α粒子在PCa中的注入。前列腺癌α粒子注入是通过分子特异性靶标位点和针对hK2的人源化单克隆抗体hu11B6的内化来引起的,并且进一

人类激肽释放酶肽酶2(hk2)是一种前列腺特异性酶,它的表达受雄激素受体(AR)控制。AR是前列腺癌(PCa)的核心致瘤驱使因子,并且在癌症的DNA修复过程是是关键的调控因子。

最近,有研究人员报道了一个创新的治疗策略,该策略利用了激素-DNA修复回路来促使分子特异性的α粒子在PCa中的注入。前列腺癌α粒子注入是通过分子特异性靶标位点和针对hK2的人源化单克隆抗体hu11B6的内化来引起的,并且进一步的可以通过固有的DNA修复机制促进hK2(KLK2)在体内的表达来促进上述作用。 Hu11B6标记的锕-225单独注射能够根除疾病,并且在动物模型中能够显著的延长生存。

另外,由α粒子注入引起的DNA损伤能够诱导AR和随后的KLK2的表达,产生一种特殊的前馈调节机制,该机制能够增加hu11B6的结合能力。在非灵长类动物模型中的成像数据支持了在男性中使用hu11B6的可能性。

原始出处:

Michael R. McDevitt, Daniel L. J. Thorek, Takeshi Hashimoto et al. Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun. 24 April 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087333, encodeId=20f1208e333ef, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Dec 27 15:56:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882997, encodeId=ca3b188299e07, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Apr 09 22:56:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350534, encodeId=dcaa135053488, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 02 01:56:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586103, encodeId=14f4158610320, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed May 02 01:56:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310697, encodeId=7eab31069ec1, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Mon Apr 30 11:24:17 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
    2018-12-27 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087333, encodeId=20f1208e333ef, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Dec 27 15:56:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882997, encodeId=ca3b188299e07, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Apr 09 22:56:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350534, encodeId=dcaa135053488, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 02 01:56:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586103, encodeId=14f4158610320, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed May 02 01:56:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310697, encodeId=7eab31069ec1, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Mon Apr 30 11:24:17 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
    2019-04-09 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087333, encodeId=20f1208e333ef, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Dec 27 15:56:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882997, encodeId=ca3b188299e07, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Apr 09 22:56:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350534, encodeId=dcaa135053488, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 02 01:56:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586103, encodeId=14f4158610320, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed May 02 01:56:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310697, encodeId=7eab31069ec1, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Mon Apr 30 11:24:17 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087333, encodeId=20f1208e333ef, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Dec 27 15:56:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882997, encodeId=ca3b188299e07, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Apr 09 22:56:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350534, encodeId=dcaa135053488, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 02 01:56:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586103, encodeId=14f4158610320, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed May 02 01:56:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310697, encodeId=7eab31069ec1, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Mon Apr 30 11:24:17 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
    2018-05-02 jeanqiuqiu
  5. [GetPortalCommentsPageByObjectIdResponse(id=2087333, encodeId=20f1208e333ef, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Dec 27 15:56:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882997, encodeId=ca3b188299e07, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Apr 09 22:56:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350534, encodeId=dcaa135053488, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 02 01:56:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586103, encodeId=14f4158610320, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed May 02 01:56:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310697, encodeId=7eab31069ec1, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Mon Apr 30 11:24:17 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
    2018-04-30 13718711b3m

    学习了.获益匪浅.感谢分享

    0

相关资讯

Eur J Cancer:卡巴他赛在激发试验在重度治疗转移难治性前列腺癌患者中的疗效分析

之前的转移性去势难治性前列腺癌(mCRPC)治疗选择多烯紫杉醇(DOC)、卡巴他赛(CABA)和新激素治疗(NHT)。因此,治疗选择有限。DOC的再激发由于毒性的积累,使用也是受限的。最近,有研究人员调查了CABA再激发在mCRPC中治疗的活性和安全性。研究总共包括了562名患者,其中69名患者接受了CABA再激发(25 mg/m2 q3w, 58%; 20 mg/m2 q3w, 27.5%; 其

CLIN CANCER RES:STAT5A/B阻滞使前列腺癌对放疗敏感

器官局限性前列腺癌的标准治疗措施是手术或放疗,局部晚期前列腺癌通常只进行放疗或联合去势治疗。CLIN CANCER RES近期发表了一篇文章,研究Stat5a/b是否参与前列腺癌双链DNA断裂修复以及Stat5阻滞是否可以使前列腺癌对放疗敏感。

BJU Int:去势难治性前列腺癌(CRPC)患者中,间断性多烯紫杉醇治疗与持续性多烯紫杉醇治疗比较

最近,有研究人员在转移性趋势难治性(mCRPC)患者中调查了间断性间断性多烯紫杉醇治疗与持续性多烯紫杉醇治疗的优劣。研究包括了187名化疗的mCRPC患者,这些患者分配到两个不同的小组中:间断性多烯紫杉醇和持续性多烯紫杉醇。在两个小组中,多烯紫杉醇使用量为每周35mg/m2或者每3周75mg/m2。初级结果为一年生存率,次级结果为总生存、无进展自由生存(PFS)、治疗失败中位时间(TTF)和毒性。

Sci Rep:STEAP2敲除能够减少前列腺癌细胞的入侵能力

与正常前列腺比较,前列腺-2的六次跨膜上皮抗原(STEAP2)表达在前列腺癌中增加,表明了STEAP2也许能够促进前列腺癌的恶化。最近,有研究人员进行了旨在阐明STEAP2在前列腺致瘤过程中的功能作用情况和评估将其敲除后是否能够减少前列腺癌细胞侵入能力的研究。研究人员将STEAP2 siRNA转化进入PC3和LNCaP细胞系中,并且分析了增殖、迁移、入侵和基因表达情况。研究人员根据格林森得分情况,

Prostate:棕榈酸酯和胰岛素对PNT1A和PC3前列腺细胞的细胞迁移和在增殖刺激性影响研究

之前的研究表明了肥胖和前列腺癌之间具有潜在的相关性。二甲双胍是一种抗糖尿病药物,并且还具有抗细胞增殖作用,且用于癌症治疗。然而,在强力的增殖刺激条件下,比如肥胖,二甲双胍的作用并不确定。因此,最近有研究人员分析了饱和脂肪酸和/或胰岛素在高密度或者有或没有二甲双胍情况下对前列腺细胞的增殖和迁移的影响。研究发现,PNT1A和PC3细胞在棕榈酸酯(HF)处理下具有更强烈的增殖作用,然而胰岛素(HI)处理

Prostate:在非转移性去势难治性前列腺癌患者中,早期雄激素受体靶向药物治疗能够提高总生存

最近,有研究人员评估了雄激素靶向药物(ARAT)在非转移性去势难治性前列腺癌(nmCRPC)和mCPRC患者中的作用。在他们的回顾性研究中,包括了114名患有CRPC但在诊断时没有转移的患者,他们在最初进行的是化疗。所有的患者在2014年7月到2017年3月期间接受了ARAT治疗。研究人员根据ARAT诱导的转移性状态将患者分为nmCRPC组(n=81)和mCRPC组(n=33)。研究发现,基线人口